GDRX
GoodRx Holdings, Inc.
GDRX's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over GDRX overall, supported by stronger fundamentals and stronger valuation.
GDRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
GDRX's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GDRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $3.51 | — |
| Cheap | 35x | $1.38 | -61% |
| Fair | 65x | $2.60 | -26% |
| Current | 88x | $3.51 | — |
| Expensive | 213x | $8.51 | +142% |
Historical ranges are pointers, not guarantees.
GDRX's PE is in its fair range at 88x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over GDRX in the historical PE scenario, which offers more potential upside but is not a forecast.
GDRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for GDRX, with profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over GDRX on the outlook, with more favorable profitability expectations.
GDRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.35 | +778% |
| Q2 2026 | $0.04 | -56% |
| Q1 2026 | $0.06 | -14% |
| Q4 2025 | $0.09 | +125% |
| Q3 2025 | $0.08 | +$0.11 |
| Q2 2025 | $0.09 | +$0.22 |
| Q1 2025 | $0.07 | +$0.08 |
| Q4 2024 | $0.04 | +$0.06 |
| Q3 2024 | -$0.03 | -200% |
GDRX's earnings per share have fallen from their peak: $0.04 over the past year, against $0.20 in early 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over GDRX on earnings, with more consistent year-over-year improvement.
GDRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $200.4M | -1.3% |
| Q1 2026 | $194M | -4.4% |
| Q4 2025 | $194.8M | -1.9% |
| Q3 2025 | $196M | +0.4% |
| Q2 2025 | $203.1M | +1.2% |
| Q1 2025 | $203M | +2.6% |
| Q4 2024 | $198.6M | +1% |
| Q3 2024 | $195.3M | +8.5% |
GDRX's revenue grew through 2021 and has held roughly level since: $200M last quarter, down 1.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 12% | -1.4 points |
| Q1 2026 | 7.2% | -4.3 points |
| Q4 2025 | 12% | +2.5 points |
| Q3 2025 | 7.5% | -3 points |
| Q2 2025 | 13% | +3.3 points |
| Q1 2025 | 12% | +7.8 points |
| Q4 2024 | 9.2% | +19 points |
| Q3 2024 | 10% | +32 points |
GDRX's operating margin was 12% last quarter, down 1.4 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over GDRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over GDRX on profitability, with a higher operating margin.
GDRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $80.5M | +64% |
| Q1 2026 | $10.7M | +15% |
| Q4 2025 | $31.6M | -29% |
| Q3 2025 | $74.3M | -14% |
| Q2 2025 | $49.2M | +421% |
| Q1 2025 | $9.3M | -78% |
| Q4 2024 | $44.6M | +188% |
| Q3 2024 | $86.5M | +44% |
GDRX's free cash flow has been positive every quarter for six years: $197M over the past year, up 4% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over GDRX on cash flow, with more consistent year-over-year improvement.
GDRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +6.6M shares |
| 1 year | -2.5% | -9.1M shares |
| 3 years | -16% | -66.3M shares |
| 5 years | -19% | -80.8M shares |
| Available history | -4% | -14.5M shares |
GDRX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $2M |
| Q1 2026 | $12.6M |
| Q4 2025 | $9.4M |
| Q3 2025 | $61.1M |
| Q2 2025 | $46M |
| Q1 2025 | $99.9M |
| Q4 2024 | $188,000 |
| Q3 2024 | $5.4M |
GDRX spent $85M buying back its own shares over the past year, down 44% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GDRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 0.3x | Very low |
| Q3 2024 | 0.6x | Very low |
GDRX has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GDRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 50.9 | Neutral |
GDRX's weekly RSI is 58 (neutral) and its Stochastic is 51 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GDRX PE vs Healthcare Sector
| Metric | GDRX | Sector median | Relative |
|---|---|---|---|
| PE | 88x | 26x | 239% above |
| PE % | 63 | 33 | 30 pts above |
GDRX is trading at 88x earnings, a 239% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over GDRX on valuation relative to its sector.
GDRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.43 | 2.3% above |
| 20 week MA | $3.36 | 4.5% above |
| 50 week MA | $2.84 | 24% above |
| 100 week MA | $3.56 | 1.4% below |
| 200 week MA | $4.98 | 30% below |
GDRX has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 30% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over GDRX on trend strength, trading above more of its moving averages.
GDRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $52.0 | $46.3 | -11% |
| 2021 | $46.3 | $33.6 | -28% |
| 2022 | $33.6 | $4.59 | -86% |
| 2023 | $4.59 | $6.70 | +46% |
| 2024 | $6.70 | $4.62 | -31% |
| 2025 | $4.62 | $2.75 | -40% |
| 2026 YTD | $2.75 | $3.51 | +28% |
GDRX has finished lower in five of the last six years. It's up 28% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over GDRX on returns for 2026, with the stronger performance.